Hypersensitivity  >>  budesonide inhalation suspension  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide inhalation suspension / Generic mfg.
P202, NCT00554970: A Study of 2 Doses of MAP0010 in Adult Asthmatics

Completed
2
32
US
MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg, Pulmicort Respules®, Budesonide inhalation suspension 0.5mg
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Asthma
01/08
03/08

Download Options